Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is projected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $37.17 million for the quarter.

Editas Medicine Stock Performance

NASDAQ:EDIT opened at $1.74 on Wednesday. The company has a market cap of $143.64 million, a price-to-earnings ratio of -0.68 and a beta of 1.94. Editas Medicine has a 52-week low of $1.12 and a 52-week high of $11.58. The stock’s fifty day moving average price is $1.34 and its two-hundred day moving average price is $2.62.

Analysts Set New Price Targets

EDIT has been the subject of several analyst reports. Barclays lowered their price target on shares of Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. Chardan Capital reiterated a “neutral” rating on shares of Editas Medicine in a research report on Friday, December 13th. Evercore ISI lowered their price target on shares of Editas Medicine from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, December 16th. Royal Bank of Canada decreased their target price on Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating for the company in a research report on Friday, December 13th. Finally, Wells Fargo & Company cut Editas Medicine from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $7.00 to $4.00 in a research note on Wednesday, December 11th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.